Belpointe Asset Management LLC Buys New Stake in Organon & Co. $OGN

Key Points

• Belpointe Asset Management LLC invested approximately $531,000 in Organon & Co., acquiring 35,648 shares during the first quarter.
• Analysts have a consensus rating of "Moderate Buy" for Organon & Co. with a target price set at $17.33.
• Organon & Co. reported a net margin of 11.15% and quarterly earnings of $1.00 EPS, beating expectations.

Belpointe Asset Management LLC bought a new position in Organon & Co. (NYSE:OGN - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 35,648 shares of the company's stock, valued at approximately $531,000.

A number of other large investors have also recently bought and sold shares of the business. Massachusetts Financial Services Co. MA increased its stake in shares of Organon & Co. by 8.3% during the first quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company's stock valued at $159,553,000 after acquiring an additional 820,378 shares during the period. LSV Asset Management grew its position in Organon & Co. by 6.1% in the first quarter. LSV Asset Management now owns 7,980,775 shares of the company's stock worth $118,834,000 after buying an additional 455,699 shares during the last quarter. Private Management Group Inc. grew its position in Organon & Co. by 1.1% in the first quarter. Private Management Group Inc. now owns 2,142,010 shares of the company's stock worth $31,895,000 after buying an additional 22,722 shares during the last quarter. Northern Trust Corp grew its position in Organon & Co. by 7.4% in the first quarter. Northern Trust Corp now owns 2,056,416 shares of the company's stock worth $30,620,000 after buying an additional 142,301 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Organon & Co. by 126.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company's stock worth $21,370,000 after buying an additional 801,307 shares during the last quarter. Institutional investors own 77.43% of the company's stock.

Analysts Set New Price Targets

Separately, BNP Paribas upgraded shares of Organon & Co. to a "strong-buy" rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.33.

Organon & Co. Stock Up 3.9%

Shares of NYSE:OGN traded up $0.41 during trading on Thursday, reaching $10.86. 3,834,215 shares of the company traded hands, compared to its average volume of 3,507,733. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98. Organon & Co. has a 1-year low of $8.01 and a 1-year high of $20.48. The firm has a fifty day simple moving average of $9.68 and a 200 day simple moving average of $10.76. The firm has a market cap of $2.82 billion, a P/E ratio of 4.04, a price-to-earnings-growth ratio of 0.95 and a beta of 0.60.

Organon & Co. (NYSE:OGN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping analysts' consensus estimates of $0.94 by $0.06. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.55 billion. During the same quarter in the previous year, the business earned $1.12 EPS. The business's revenue was down .8% on a year-over-year basis. Organon & Co. has set its FY 2025 guidance at EPS. Analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Investors of record on Friday, August 15th were paid a $0.02 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a yield of 0.7%. Organon & Co.'s payout ratio is presently 2.97%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.